<SEC-DOCUMENT>0000909327-25-000025.txt : 20250819
<SEC-HEADER>0000909327-25-000025.hdr.sgml : 20250819
<ACCEPTANCE-DATETIME>20250818205941
ACCESSION NUMBER:		0000909327-25-000025
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20250818
FILED AS OF DATE:		20250819
DATE AS OF CHANGE:		20250818

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Suzano S.A.
		CENTRAL INDEX KEY:			0000909327
		STANDARD INDUSTRIAL CLASSIFICATION:	PAPER MILLS [2621]
		ORGANIZATION NAME:           	04 Manufacturing
		EIN:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38755
		FILM NUMBER:		251229452

	BUSINESS ADDRESS:	
		STREET 1:		AV. PROFESSOR MAGALHAES NETO, 1,752
		STREET 2:		10TH FLOOR, ROOMS 1010 AND 1011
		CITY:			SALVADOR - BA
		STATE:			D5
		ZIP:			41 810-012
		BUSINESS PHONE:		551121384588

	MAIL ADDRESS:	
		STREET 1:		AV. BRIGADEIRO FARIA LIMA, 1,355
		STREET 2:		7TH FLOOR
		CITY:			PINHEIROS, SAO PAULO - SP
		STATE:			D5
		ZIP:			01 452-919

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Suzano Papel e Celulose S.A.
		DATE OF NAME CHANGE:	20180322

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	COMPANHIA SUZANO DE PAPEL E CELULOSE                    /FI
		DATE OF NAME CHANGE:	19930719
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>a20250818-suzano_6kxminute.htm
<DESCRIPTION>6-K
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i71d199ae1e2942148537bc65f1a1a119_1"></div><div style="min-height:36pt;width:100%"><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:13pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:4pt solid #000;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES<br>SECURITIES AND EXCHANGE COMMISSION<br>Washington, DC 20549</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:22pt;font-weight:700;line-height:120%">FORM&#160;6-K</font></div><div style="margin-bottom:30pt;margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">REPORT OF FOREIGN PRIVATE ISSUER<br>PURSUANT TO RULE 13a-16 OR 15d-16<br>UNDER THE SECURITIES EXCHANGE ACT OF 1934</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">For the month of August, 2025.</font></div><div style="margin-bottom:30pt;margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commission File Number 001-38755</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Suzano S.A.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><br></font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUZANO INC. <br></font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Translation of Registrant&#8217;s Name into English)</font></div><div style="margin-bottom:30pt;margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Av. Professor Magalhaes Neto, 1,752<br>10th Floor, Rooms 1010 and 1011<br>Salvador, Brazil 41 810-012<br></font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Address of principal executive office)</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Indicate by check mark whether the registrant files or will file annual reports under cover of Form&#160;20-F or Form&#160;40-F.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br>Form&#160;20-F &#9745;&#160;&#160;&#160;&#160;Form&#160;40-F &#9744;</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Indicate by check mark if the registrant is submitting the Form&#160;6-K in paper as permitted by Regulation S-T Rule&#160;101(b)(1)&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#9744;</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Indicate by check mark if the registrant is submitting the Form&#160;6-K in paper as permitted by Regulation S-T Rule&#160;101(b)(7)&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#9744;</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:13pt"><td colspan="3" style="border-bottom:4pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div></div></div><div id="i71d199ae1e2942148537bc65f1a1a119_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:150%">Enclosures&#58;</font></div><div><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:150%;text-decoration:underline"><a href="a20250818-minutesoftheboar.htm" style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:150%;text-decoration:underline">Exhibit 99.1&#160;&#8211; Minutes of the Board of Directors' Meeting</a></font></div><div style="text-align:center"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i71d199ae1e2942148537bc65f1a1a119_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:150%">SIGNATURE</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:150%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date&#58; August 18</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">, 2025</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.275%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.973%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.452%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUZANO S.A.</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Marcos Moreno Chagas Assump&#231;&#227;o</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name&#58;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marcos Moreno Chagas Assump&#231;&#227;o</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vice-President of Finance and Investor Relations</font></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a20250818-minutesoftheboar.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i4d57cf8536e547e8bae3b546d2b780f9_1"></div><div style="min-height:66.96pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 99.1</font></div></div><div style="margin-top:4pt;padding-left:80.02pt;padding-right:80.02pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11.5pt;font-weight:700;line-height:120%">SUZANO</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11.5pt;font-weight:700;letter-spacing:-0.021em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11.5pt;font-weight:700;letter-spacing:-0.017em;line-height:120%">S.A.</font></div><div style="margin-top:1.55pt;padding-left:80.02pt;padding-right:80.02pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11.5pt;font-weight:400;line-height:130%">Publicly</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11.5pt;font-weight:400;letter-spacing:-0.03em;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11.5pt;font-weight:400;line-height:130%">Held</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11.5pt;font-weight:400;letter-spacing:-0.03em;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11.5pt;font-weight:400;line-height:130%">Company</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11.5pt;font-weight:400;letter-spacing:-0.03em;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11.5pt;font-weight:400;line-height:130%">with</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11.5pt;font-weight:400;letter-spacing:-0.03em;line-height:130%"> A</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11.5pt;font-weight:400;line-height:130%">uthorized</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11.5pt;font-weight:400;letter-spacing:-0.043000000000000003em;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11.5pt;font-weight:400;line-height:130%">Capital </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11.5pt;font-weight:400;line-height:100%">CNPJ&#47;ME No. 16.404.287&#47;0001-55</font></div><div style="padding-left:80.27pt;padding-right:80.27pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11.5pt;font-weight:400;line-height:13.00pt">NIRE</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11.5pt;font-weight:400;letter-spacing:-0.004em;line-height:13.00pt"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11.5pt;font-weight:400;line-height:13.00pt">No.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11.5pt;font-weight:400;letter-spacing:-0.004em;line-height:13.00pt"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11.5pt;font-weight:400;letter-spacing:-0.008em;line-height:13.00pt">29.300.016.331</font></div><div style="margin-top:3.1pt"><font><br></font></div><div style="padding-left:80.07pt;padding-right:80.07pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11.5pt;font-weight:700;line-height:125%">MINUTES</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11.5pt;font-weight:700;letter-spacing:-0.039em;line-height:125%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11.5pt;font-weight:700;line-height:125%">OF</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11.5pt;font-weight:700;letter-spacing:-0.03em;line-height:125%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11.5pt;font-weight:700;line-height:125%">THE</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11.5pt;font-weight:700;letter-spacing:-0.03em;line-height:125%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11.5pt;font-weight:700;line-height:125%">BOARD</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11.5pt;font-weight:700;letter-spacing:-0.034em;line-height:125%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11.5pt;font-weight:700;line-height:125%">OF</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11.5pt;font-weight:700;letter-spacing:-0.03em;line-height:125%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11.5pt;font-weight:700;line-height:125%">DIRECTORS' MEETING HELD ON AUGUST 14, 2025</font></div><div style="margin-top:1.05pt;padding-left:1.05pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%;text-decoration:underline">1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%;padding-left:8.72pt;text-decoration:underline">Date, Time and Place</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">&#58; August 14, 2025, at 8 a.m., the Board of Directors (&#34;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%;text-decoration:underline">Board</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">&#34;) of Suzano S.A. (&#34;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%;text-decoration:underline">Suzano</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">&#34; or &#34;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">&#34;) met by digital form (videoconference).</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%;text-decoration:underline">2.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%;padding-left:8.72pt;text-decoration:underline">Attendance</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%">&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">The following Directors of the Company attended the meeting&#58; David Feffer (Chairman of the Board), Daniel Feffer and Nildemar Secches (Vice-Chairmans of the Board), Gabriela Feffer Moll, Maria Priscila Rodini Vansetti Machado, Paulo Rogerio Cafarelli, Paulo Sergio Kakinoff, Rodrigo Calvo Galindo and Walter Schalka (&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%;text-decoration:underline">Directors</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">&#8221;). In addition, Jos&#233; Alberto de Abreu, Statutory Executive Director without specific designation, Marcos Moreno Chagas Assump&#231;&#227;o, CFO and Investor Relations Director and Mr. Jo&#227;o Vitor Zocca Moreira, as Secretary, attended the meeting as guests.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%;text-decoration:underline">3.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%;padding-left:8.72pt;text-decoration:underline">Call Notice</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%">&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">Pursuant to item 6.3 of the Internal Regulations of the Board, the call notice was dispensed, considering that all the members of the Board were present.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%;text-decoration:underline">4.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%;padding-left:8.72pt;text-decoration:underline">Chairman and Secretary&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">Mr. David Feffer presided over the meeting and Mr. Jo&#227;o Vitor Zocca Moreira acted as the secretary.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%;text-decoration:underline">5.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%;padding-left:8.72pt;text-decoration:underline">Agenda</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%">&#58; (1) </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">analysis and resolution on the issuance of the first (1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.47pt;font-weight:400;line-height:108%;position:relative;top:-3.48pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">) issuance of financial liquidation rural product notes, book-entry, in up to three (3) series, for public distribution, by the Company (&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%;text-decoration:underline">CPR-Fs</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">&#8221;), in the total amount of BRL 2,000,000,000.00 (two billion Brazilian </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:108%">reais</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">) (&#34;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%;text-decoration:underline">Issuance</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">&#34;), which will be object of a public distribution offering, according to the automatic distribution registration procedure, pursuant to Law No. 6,385, of December 7, 1976, as amended (&#34;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%;text-decoration:underline">Law 6,385</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">&#34;), of the Resolution of the Brazilian Securities and Exchange Commission (&#34;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%;text-decoration:underline">CVM</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">&#34;) No. 160, of July 13, 2022, as amended (&#34;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%;text-decoration:underline">CVM Resolution 160</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">&#34;) and of the other applicable legal and regulatory provisions (&#34;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%;text-decoration:underline">Offering</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">&#34;), under a firm-commitment placement regime&#59; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%">(2) </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">analysis and resolution on the hiring of service providers necessary to execute the Offering, including, without limitation, the financial institutions integrating the securities system responsible for the placement and intermediation of the Offering (&#34;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%;text-decoration:underline">Underwriters</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">&#34;), the CPR-Fs agent, the liquidation agent, the bookkeeping agent, the rating agency and the legal counsels (&#34;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%;text-decoration:underline">Service Providers</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">&#34;), through the signing of the respective hiring instruments&#59; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%">(3) </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">analysis and resolution for the execution of all and any instruments, contracts and documents and their eventual amendments and for the practice of all the necessary or suitable acts for the formalization of the above resolutions, including the amendment to the Indenture to reflect the final volume of the CPR-Fs offering&#59; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%">(4) </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">the execution of derivative transactions linked to the CPR-Fs, with the exclusive purpose of hedge or protection that does not allow the leveraging of risk&#59; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%">(5) </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">authorize the Company's officers and&#47;or their legally appointed attorneys-in-fact, pursuant to the provisions of the Company's Bylaws, to represent the Company in the practice of all the necessary or suitable acts for the formalization of the above resolutions, including, without limitation, the execution of the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:108%">Terms and </font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.820%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1.3pt;padding-left:3.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;letter-spacing:-0.058em;line-height:120%">1</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 99.1</font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:108%">Conditions of the 1st (First) Issuance of Financial Liquidation Rural Product Notes, Book-Entry, in up to 3 (three) Series, for Public Distribution, Under the Automatic Distribution Registration Procedure, of Suzano S.A.&#8221; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">(&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%;text-decoration:underline">Indenture</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">&#8221;) and any amendments thereto, the CPR-Fs distribution agreement (&#34;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%;text-decoration:underline">Distribution Agreement</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">&#34;), the instruments for contracting the Service Providers and other documents required for registering the CPR-Fs with the </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:108%">B3 S.A. - Brasil, Bolsa, Balc&#227;o </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">(&#34;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%;text-decoration:underline">B3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">&#34;), among other documents&#59; and </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%">(6) </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">analysis and resolution on the ratification of all the acts that have been performed by the Company's management related to the above matters.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%;text-decoration:underline">6.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%;padding-left:8.72pt;text-decoration:underline">Minutes in Summary Form</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%">&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">The Directors present unanimously approved the drawing up of these minutes in summary form.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%;text-decoration:underline">7.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%;padding-left:8.72pt;text-decoration:underline">Resolutions</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%">&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">The Directors present unanimously and without reservations approved&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">I. the execution of the Issuance and the Offering, under the terms and conditions below&#58;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%">a.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%;padding-left:8.88pt">Use of Proceeds</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">. The net funds raised by the Company through the Issuance will be used for the formation and exploitation of homogeneous forests, as well as the conservation of native forests&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%">b.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%;padding-left:8.37pt">Distribution</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">. The CPR-Fs will be subject to public distribution, under the automatic registration distribution regime, with a firm placement guarantee for the entirety of the CPR-Fs, i.e., 2,000,000 (two million) CPR-Fs, in accordance with CVM Resolution 160, individually and not jointly among the Underwriters, in accordance with the terms and conditions of the Distribution Agreement&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%">c.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%;padding-left:9.78pt">Number of the Issuance</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">. The CPR-Fs represent the 1st (first) issuance of financial liquidation rural product notes, book-entry, for public distribution by the Company&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%">d.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%;padding-left:8.37pt">Subscription Term and Form of Subscription and Payment</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">. The CPR-Fs will be subscribed and paid-in, at any time, from the date of the initial distribution, as informed in the initial distribution announcement, to be released pursuant to article 13 of CVM Resolution 160, during the CPR-Fs distribution period set forth in article 48 of CVM Resolution 160, in accordance with the procedures of B3, observing the subject to the Distribution Schedule (as shall be defined in the Indenture).The payment price of the CPR-Fs (i) on the first Payment Date (as defined below) of the respective series of CPR-Fs, will be the Nominal Unit Value, for the three series of CPR-Fs, (ii) on Payment Dates subsequent to the first Payment Date, will be (ii.a) the Nominal Unit Value, in the case of the First Series CPR-Fs&#59; or (ii.b) the Updated Nominal Unit Value of the Second Series CPR-Fs and the Third Series CPR-Fs, in the case of the Second Series CPR-Fs and the Third Series CPR-Fs, in both cases increased by the Remuneration of the respective series of CPR-Fs, calculated </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:108%">pro rata temporis </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">from the first Payment Date until the effective payment date of the respective series of CPR-Fs (&#34;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%;text-decoration:underline">Payment Price</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">&#34;), and may also, on any Payment Date, be subscribed with a premium or discount, as may be defined at the time of subscription of the CPR-Fs, provided that, if applicable, the premium or discount, as the case may be, shall be applied equally to all CPR-Fs of the same series </font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.820%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1.3pt;padding-left:3.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;letter-spacing:-0.058em;line-height:120%">2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 99.1</font></div></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">subscribed and paid for on the same payment date (&#34;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%;text-decoration:underline">Payment Date</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">&#8221;). The CPR-Fs shall be paid up in cash and in local currency on the respective Payment Date at the applicable Payment Price&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:112%">(e) Monetary Adjustment of the CPR-Fs.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">(i) The Nominal Unit Value or the remaining balance of the Nominal Unit Value, as the case may be, of the First Series CPR-Fs, will not be monetarily restated&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">(ii) The Nominal Unit Value or the remaining balance of the Nominal Unit Value of the Second Series CPR-Fs and Third Series CPR-Fs will be updated by the accumulated variation of the IPCA, disclosed monthly by the IBGE, calculated in an exponential and cumulative manner </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:108%">pro rata temporis </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">basis per Business Days, from the first Payment Date of the Second Series CPR-Fs and Third Series CPR-Fs until the date of their effective payment, and the product of the adjustment will be incorporated into the Nominal Unit Value or the remaining balance of Nominal Unit Value, as the case may be, of the Second Series CPR-Fs and Third Series CPR-Fs automatically (&#34;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%;text-decoration:underline">Monetary</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%;text-decoration:underline">Adjustment</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">&#34; and &#34;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%;text-decoration:underline">Updated Nominal Unit Value</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">&#34;, respectively), and calculated in accordance with the formula to be set forth in the Indenture.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%">(f) Distribution, Trading and Electronic Custody</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">. The CPR-Fs will be deposited at B3 for&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%">(i) </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">distribution in the primary market through MDA - Securities Distribution Module, managed and operated by B3, with the distribution being financially settled through B3&#59; and </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%">(ii) </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">trading in the secondary market, subject to the provisions of the Indenture, in both cases through Cetip21 &#8211; Securities and Securities (&#34;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%;text-decoration:underline">CETIP21</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">&#34;), with the distribution being financially settled through B3, with the trades financially settled and the CPR-Fs held electronically at B3, including for the purposes of item II, article 12, of Law 8,929&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%">(g) Total Amount of the Issuance</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">. The total Issuance amount will be BRL 2,000,000,000.00 (two billion Brazilian reais), on the Issuance Date (&#34;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%;text-decoration:underline">Total Amount</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%;text-decoration:underline">of the Issuance</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">&#34;)&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%">(h) Quantity of CPR-Fs</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">. There will be issued 2.000.000 (two thousand) CPR-Fs. The amount of CPR-Fs allocated to each Series will be defined within the scope of the Bookbuilding Procedure, observing the Communicating Vessel System, the Maximum Volume of the First Series, the Minimum Volume of the Second Series and the Minimum CPR-Fs Volume of the Third Series (as defined below)&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%">(i) Nominal Unit Value</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">. The CPR-Fs will have a Nominal Unit Value of BRL 1,000.00 (one thousand Brazilian </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:108%">reais)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">, on the Issuance Date (&#8220;Nominal Unit Value&#8221;)&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%">(j) Number of Series</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">. Given that the Company is carrying out in the context of this Issuance the distribution of three (3) distinct series of CPR-Fs, each with its own specific and mutually fungible characteristics, the Company assigns to each of these series the nomenclature of &#34;Series&#34;, with the CPR-Fs of the first series referred to as &#34;First Series CPR-Fs &#34;, the CPR-Fs of the second series, &#34;Second Series CPR-Fs&#34; and </font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.820%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1.3pt;padding-left:3.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;letter-spacing:-0.058em;line-height:120%">3</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 99.1</font></div></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">the CPR-Fs of the third series, &#34;Third Series CPR-Fs&#34;&#59; and, together, &#34;CPR-Fs&#34;), noting that the allocation of CPR-Fs between the Series should occur according to the system of communicating vessels, through which the amount of CPR-Fs of one series should be reduced from the total amount of CPR-Fs to be allocated in the other series (&#34;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%;text-decoration:underline">System of Communicating Vessels</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">&#34;), being certain that the following will be issued&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%">(i) </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">a maximum of 500,000 (five hundred thousand) First Series CPR- Fs, equivalent to R$ 500,000,000.00 (five hundred million reais) (&#34;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%;text-decoration:underline">Maximum Volume</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%;text-decoration:underline">of the First Series CPR-Fs</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">&#34;)&#59; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%">(ii) </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">at least 750,000 (seven hundred and fifty thousand) Second Series CPR-Fs, equivalent to R$ 750,000,000.00 (seven hundred and fifty million reais) (&#34;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%;text-decoration:underline">Minimum Volume of the Second Series CPR-Fs</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">&#34;)&#59; and </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%">(iii) </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">at least 750,000 (seven hundred and fifty thousand) Third Series CPR-Fs, equivalent to R$ 750,000,000.00 (seven hundred and fifty million reais) (&#34;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%;text-decoration:underline">Minimum Volume of the</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%"> Third Series CPR-Fs&#34;)&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%">(k) Form, Type and Proof of Title</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">. the CPR-Fs will be issued in registered and book- entry form, and, for all legal purposes, the ownership of the CPR-Fs will be proven by the statement issued by the Bookkeeper and, additionally, with respect to the CPR-Fs that are held electronically at B3, as the case may be, an extract will be issued by the latter in the name of the CPR-Fs Holder, which will serve as proof of ownership of such CPR-Fs&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:112%">(I) Issuance Date</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">. For all legal effects, the CPR-Fs issuance date will be that defined</font></div><div style="text-align:justify;text-indent:35.59pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">in the Indenture (&#8220;Issuance Date&#8221;)&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%">(m) Yield Start Date</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">&#58; For all legal purposes and effects, the yield start date&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%">(i) </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">of the First Series CPR-Fs, will be the first Payment Date of the First Series CPR-Fs&#59; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%">(ii) </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">of the Second Series CPR-Fs, will be the first Payment Date of the Second Series CPR- Fs&#59; and </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%">(iii) </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">of the Third Series CPR-Fs, will be the first Payment Date of the CPR-Fs Third Series&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:112%">(n) Term and Maturity Date.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%;text-decoration:underline">(i) Term and Maturity Date of the First Series CPR-Fs</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">. Subject to the provisions of the Indenture, the term of the First Series CPR-Fs will be 8 (eight) years from the Issuance Date, maturing on a date to be established in the Indenture (&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%;text-decoration:underline">Maturity Date of the First Series CPR-Fs</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">&#8221;)&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%;text-decoration:underline">(ii) Term and Maturity Date of the Second Series CPR-Fs</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">. Subject to the provisions of the Indenture, the term of the Second Series CPR-Fs will be 10 (ten) years from the Issuance Date, maturing on a date to be established in the Indenture (&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%;text-decoration:underline">Maturity Date of the Second Series CPR-Fs</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">&#8221;)&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%;text-decoration:underline">(iii) Term and Maturity Date of the Third Series CPR-Fs.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%"> Subject to the provisions of the Indenture, the term of the Third Series CPR-Fs will be 12 (twelve) years from the Issuance Date, maturing on a date to be established in the Indenture (&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%;text-decoration:underline">Maturity Date of the Third Series CPR-Fs</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">&#8221; and, together with the Maturity Date of the First Series CPR-Fs and the Maturity Date of the Second Series CPR-Fs, the &#34;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%;text-decoration:underline">Maturity Dates</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">&#34;).</font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.820%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1.3pt;padding-left:3.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;letter-spacing:-0.058em;line-height:120%">4</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 99.1</font></div></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%">(o) Amortization of CPR-Fs</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">. Except for the hypotheses of early maturity and early liquidation provided for in the Indenture, </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%">(i) </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">the remaining balance of the Nominal Unit Value of the First Series CPR-Fs will be amortized in a single installment, on the Maturity Date of the First Series CPR-Fs&#59; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%">(ii) </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">the remaining balance of the Updated Nominal Unit Value of the Second Series CPR-Fs will be amortized in a single installment on the Maturity Date of the Second Series CPR-Fs&#59; and </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%">(iii) </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">the remaining balance of the Updated Nominal Unit Value of the Third Series CPR-Fs will be amortized in a single installment on the Maturity Date of the Third Series CPR-Fs (each of the dates, &#34;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%;text-decoration:underline">Date of Amortization</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">&#34;)</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:112%">(p) Remuneration of the CPR-Fs&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%;text-decoration:underline">(i) Remuneration of the First Series CPR-Fs.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%"> The Nominal Unit Value or the balance of the Nominal Unit Value of the First Series CPR-Fs, as the case may be, will bear interest equivalent to 96.50% (ninety-six integers and fifty hundredths percent) of the average daily rates of the one-day Interbank Deposit (DI), &#34;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:108%">over extra grupo</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">&#34; (&#34;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%;text-decoration:underline">DI Rate</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">&#34;), expressed as a percentage per annum, based on 252 (two hundred and fifty-two) Business Days, calculated and disclosed daily by B3 in the daily information available on its website (</font><font style="color:#0462c1;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%;text-decoration:underline">http&#58;&#47;&#47;www.b3.com.br</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">) (&#34;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%;text-decoration:underline">Remuneration of the First Series CPR-Fs</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">&#34;), calculated exponentially and cumulatively pro rata temporis per Business Day elapsed, from the first Payment Date of the First Series CPR-Fs or the immediately preceding Payment Date of the Remuneration of the First Series CPR-Fs, as the case may be, until the date of actual payment. The Remuneration of the First Series CPR-Fs will be calculated in accordance with the formula to be described in the Indenture&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%;text-decoration:underline">(ii) Remuneration of the Second Series CPR-Fs.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%"> The Updated Nominal Unit Value or the balance of the Updated Nominal Unit Value of the Second Series CPR- Fs, as the case may be, will bear interest corresponding to a certain percentage per annum, to be defined on the date of the Bookbuilding Procedure, which will be equivalent to the higher rate (&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%;text-decoration:underline">Maximum Rate for</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%;text-decoration:underline">the Second Series CPR-Fs</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">&#8221;) between&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%">(a) </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">the internal rate of return of the IPCA+ Treasury with Semi-annual Interest (new name of the National Treasury Note, Series B &#8211; NTN-B), maturing on May 15, 2035, based on the indicative price disclosed by ANBIMA on its website </font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">(www.anbima.com.br),</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%"> as calculated at the close of the Business Day on the date of the Bookbuilding Procedure, plus an exponential negative rate of -0.45% (negative forty-five hundredths of a percent) per annum, based on 252 (two hundred and fifty- two) Business Days&#59; or </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%">(b) </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">a certain percentage to be defined per annum, based on 252 (two hundred and fifty-two) Business Days (&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%;text-decoration:underline">Second Series</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%;text-decoration:underline">CPR-Fs Remuneration</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">&#8221;), from the first Payment Date or the Second Series CPR-Fs Remuneration Payment Date (as defined below) immediately prior (inclusive), as the case may be, until the date of actual payment. The Second Series CPR-Fs Remuneration shall </font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.820%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1.3pt;padding-left:3.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;letter-spacing:-0.058em;line-height:120%">5</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 99.1</font></div></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">be calculated in accordance with the formula provided for in the Indenture&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%;text-decoration:underline">(iii) Remuneration of the Third Series CPR-Fs</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">. The Updated Nominal Unit Value or the balance of the Updated Nominal Unit Value of the Third Series CPR- Fs, as the case may be, will bear interest corresponding to a certain percentage per annum, to be defined on the date of the Bookbuilding Procedure, which will be equivalent to the higher rate (&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%;text-decoration:underline">Maximum Rate for</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%;text-decoration:underline">the Third Series CPR-Fs</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">&#8221; and, together with the Maximum Rate for First Series CPR-Fs and the Maximum Rate for Second Series CPR-Fs, &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%;text-decoration:underline">Maximum</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%;text-decoration:underline">Rate</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">&#8221;) between&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%">(a) </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">the internal rate of return of the IPCA+ Treasury with Semi-annual Interest (new name of the National Treasury Note, Series B &#8211; NTN-B), maturing on May 15, 2035, based on the indicative price disclosed by ANBIMA on its website </font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">(www.anbima.com.br),</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%"> as calculated at the close of the Business Day on the date of the Bookbuilding Procedure, plus an exponential negative rate of -0.43% (negative forty-three hundredths of a percent) per annum, based on 252 (two hundred and fifty-two) Business Days&#59; or </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%">(b) </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">a certain percentage to be defined per annum, based on 252 (two hundred and fifty-two) Business Days (&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%;text-decoration:underline">Third Series CPR-Fs</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%;text-decoration:underline">Remuneration</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">&#8221; and, together with the Remuneration of First Series CPR-Fs and Remuneration of Second Series CPR-Fs, the &#34;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%;text-decoration:underline">Remuneration</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">&#34;), from the first Payment Date or the Third Series CPR-Fs Remuneration Payment Date (as defined below) immediately prior (inclusive), as the case may be, until the date of actual payment. The Third Series CPR-Fs Remuneration shall be calculated in accordance with the formula provided for in the Indenture.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:110%">(q) Payment of the Remuneration</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:110%">. The Remuneration of the CPR-Fs will be paid, every six months, always on the 15th day of the months indicated in the Indenture&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%">(r) Bookbuilding Procedure</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">. The procedure for collecting investment intentions will be adopted, with receipt of reserves from investors, without minimum or maximum lots, to be conducted by the Underwriters, pursuant to articles. 61 and 62 of CVM Resolution 160, as well as under the terms of the Distribution Agreement, subject to the provisions of article 61, paragraphs 2 and 3, of CVM Resolution 160, through which the Underwriters will verify the market demand for the CPR-Fs, for verification and definition, together with the Company&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%">(i) </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">the final rate of the Remuneration of the Second Series CPR-Fs and the Third Series CPR-Fs, subject to the terms of the Indenture&#59; and </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%">(ii) </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">the amount of CPR-Fs to be allocated in each Series of the Issuance, according to the Communicating Vessel System and observing the Maximum Volume of the First Series CPR-Fs, the Minimum Volume of the Second Series CPR-Fs and the Minimum Volume of the Third Series CPR-Fs (&#34;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%;text-decoration:underline">Bookbuilding Procedure</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">&#34;)&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%">(s) Scheduled Renegotiation</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">. The CPR-Fs will not be subject to scheduled renegotiation&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.820%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1.3pt;padding-left:3.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;letter-spacing:-0.058em;line-height:120%">6</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 99.1</font></div></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%">(t) Risk Rating</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">. Fitch Ratings Brasil Ltda. will be hired as the risk rating agency for the CPR-Fs (&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%;text-decoration:underline">Risk Rating Agency</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">&#8221;)&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%">(u)Optional Total Early Liquidation</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">. The Company may, at its sole discretion, after twelve (12) months from the Issuance Date (inclusive), on the date specified in the Indenture, carry out the optional early liquidation of all CPR-Fs of one or all Series (&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%;text-decoration:underline">Total Optional Early Liquidation</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">&#8221;), subject to the terms and conditions set forth in the Indenture.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%">(v) Early Liquidation Offer</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">. The Company may make an early liquidation offer for all CPR-Fs of each Series, at its sole discretion, which shall be addressed to all CPR-Fs Holders of each Series subject to the Early Liquidation Offer of CPR-Fs of each Series, without distinction, ensuring equal conditions for all CPR-Fs Holders of each Series, to accept the Early Liquidation Offer of CPR-Fs of each Series of which they are holders, without distinction, ensuring equal conditions for all CPR-Fs Holders of each Series, to accept the Early Liquidation Offer for the CPR-Fs of each Series they hold, in accordance with the terms and conditions set forth in the Indenture (&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%;text-decoration:underline">Early</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%;text-decoration:underline">Liquidation Offer</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">&#8221;)&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%">(w) Optional Acquisition of CPR-Fs</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">. The Company may, at any time, acquire the CPR-Fs in the market, subject to the acceptance of the respective holder. The CPR- Fs acquired by the Company under the terms set forth herein may, at the Company's discretion, be canceled, remain in treasury or be placed back on the market. The CPR-Fs acquired by the Company to be held in treasury pursuant to this item, if and when relocated to the market, will be entitled to the same remuneration as the CPR-Fs applicable to the other CPR-Fs&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%">(x) Extraordinary Amortization</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">. The Company may, at its sole discretion, after twelve (12) months from the Issuance Date (inclusive), on the date set forth in the Indenture, carry out the optional extraordinary amortization of the CPR-Fs of one or all Series (&#34;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%;text-decoration:underline">Optional Extraordinary Amortization</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">&#34;), subject to the terms and conditions set forth in the Indenture&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%">(y) Default Charges</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">&#58; Notwithstanding the Monetary Adjustment, as applicable, and the Remuneration, in the event of default in the payment by the Company of any amount due to the CPR-Fs Holders, the overdue debts incurred and unpaid by the Company shall be subject to, regardless of notice, notification or judicial or extrajudicial interpellation </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%">(i) </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">default interest of 1% (one percent) per month, calculated </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:108%">pro rata temporis</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">, from the date of default to the date of actual payment&#59; and </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%">(ii) </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">a conventional fine, irreducible and of a non-compensatory nature, of 2% (two percent) per month, from the date of default to the date of actual payment&#59; both calculated on the amount due and unpaid (&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%;text-decoration:underline">Default Charges</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">&#8221;)&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%">(z) Early Maturity</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">&#58; The CPR-Fs Agent shall consider all obligations under the Indenture to be accelerated, automatically or not, regardless of notice, summons or notification, judicial or extrajudicial, in the occurrence of the events to be described in the Indenture, observing the respective remedy period, as applicable (each one, an &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%;text-decoration:underline">Event of Early Maturity</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">&#8221;)&#59; and</font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.820%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1.3pt;padding-left:3.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;letter-spacing:-0.058em;line-height:120%">7</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 99.1</font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:35.59pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%">(aa) Other Characteristics</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">&#58; all other characteristics of the CPR-Fs will be described in the Indenture.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">II. the hiring of the Service Providers, by means of the signature of the respective contracting instruments&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">III. the execution of all and any instruments, agreements and documents and their eventual amendments and practice of all acts necessary or suitable for the formalization of the resolutions approved above, including the amendment to the Indenture to reflect the final volume to be issued of the CPR-Fs&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:110%">IV. the execution of derivative transactions linked to the CPR-Fs, with the exclusive purpose of hedge or protection that does not allow the leveraging of risk&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">V.the authorization to the Company&#8217;s officers and&#47;or their legally constituted attorneys- in-fact, observing the provisions in the Company&#8217;s Bylaws, to represent the Company in the practice of all necessary or suitable acts for the formalization of the above resolutions, including, but not limited to the execution and negotiation of the Indenture, and, also regarding the Clauses that will define the Optional Total Early Liquidation , the Early Liquidation Offer, the Optional Acquisition of CPR-Fs and the Optional Extraordinary Amortization, the Distribution Agreement and other documents required for the registration of the CPR-Fs with the B3, among other documents&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:110%">VI. the ratification of all acts that have been practiced by the Company&#8217;s management related to the above matters.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:0.05pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%">7. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%;text-decoration:underline">Adjournment</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%">&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">There being no further business to discuss, the meeting was closed. The minutes of the meeting were drafted, read, approved and will be signed electronically by all the attending Directors, with the signatures having retroactive effect to the date of the meeting. It is noted that the documents and presentations that were the basis for the matters dealt with at this meeting have been filed in the </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:108%">Portal de Governan&#231;a</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">. Signatures&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%">Chairman of the Board&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">David Feffer. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%">Vice &#8211; Chairman of the Board</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">&#58; Jo&#227;o Vitor Zocca Moreira. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:108%">Directors&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:108%">David Feffer, Daniel Feffer, Nildemar Secches, Gabriela Feffer Moll, Maria Priscila Rodini Vansetti Machado, Paulo Rogerio Cafarelli, Paulo Sergio Kakinoff, Rodrigo Calvo Galindo e Walter Schalka. I hereby certify that this is a copy of the minutes drawn up in the proper book.</font></div><div><font><br></font></div><div style="text-align:center;text-indent:7.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">S&#227;o Paulo, SP, August 14, 2025.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center;text-indent:7.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Jo&#227;o Vitor Zocca Moreira</font></div><div style="text-align:center;text-indent:7.15pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Secretary</font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.820%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1.3pt;padding-left:3.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;letter-spacing:-0.058em;line-height:120%">8</font></div></td></tr></table></div></div></div><div id="i4d57cf8536e547e8bae3b546d2b780f9_4"></div><hr style="page-break-after:always"><div style="min-height:30.96pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 99.1</font></div></div><div style="margin-top:4.05pt"><font><br></font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.820%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1.3pt;padding-left:3.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;letter-spacing:-0.058em;line-height:120%">9</font></div></td></tr></table></div></div></div></body></html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
